XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.

Peru's sol weakens among Latam FX ahead of interest rate decision



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>EMERGING MARKETS-Peru's sol weakens among Latam FX ahead of interest rate decision</title></head><body>

Argentina inflation cools in September

Peru interest rate decision on tap

Latam MSCI stocks index up 0.5%, FX slips 0.1%

Updated at 1931 GMT

By Johann M Cherian

Oct 10 (Reuters) -Peru's sol depreciated the most among Latin American currencies on Thursday, with traders pricing in an interest rate cut by the domestic central bank, while Colombia's peso firmed, tracking higher crude prices.

Peru's sol PEN= dropped 1.3% and was on track to log its biggest one-day decline since April. Traders are expecting the local central bank to trim borrowing costs in the Andean nation by 25 basis points to 5% later in the day.

On the flip side, the local equities index .SPBLPGPT rose more than 2%.

"Recent data are broadly supportive of further normalization of the policy stance through a moderate move ... the inflation backdrop showed incremental progress even relative to the benign dynamics in recent months and inflation expectations continue to soften, approaching the 2.0% target," said analysts at Goldman Sachs.

Meanwhile, oil exporter Colombia's peso COP= appreciated 0.8% to 4,199 to the dollar, tracking crude prices that jumped over 3.5%, underpinned by a spike in fuel demand as a major storm barreled in to Florida, and supply risks in the Middle East. O/R

More broadly, an index tracking currencies in the region .MILA00000CUS dipped 0.2% against a steady dollar. Markets priced in upcoming interest rate cuts by the U.S. Federal Reserve after data showed U.S. inflation was largely on a downward trend, even though prices ticked up more-than-expected in September.

Mexico's peso MXN= was flat, while the local equity index gained more than 1%, after minutes from Bankxico's September meeting showed the central bank expects easing inflation could allow further reductions to its benchmark interest rate.

Brazil's real BRL= edged up 0.2% after hitting levels seen two weeks ago in the previous session. Finance Minister Fernando Haddad said taxing millionaires is one of the ways by which the government is planning to undertake an income tax reform.

Concerns around fiscal stability in the region's largest economy have weighed on the real recently.

Chile's peso CLP= firmed 0.4% after hitting a one-month low in the previous session, tracking a rebound in copper prices. MET/L

Currencies of major economies in the region have hit a rough patch this week, and are on track for weekly declines as the initial optimism around China's stimulus and the consequent demand for commodities out of the resources-rich region fizzled out.

MSCI's gauge for equities in the region .MILA00000PUS edged up 0.5% but was near one-month lows, with stocks in Brazil .BVSP and Colombia .COLCAP adding 0.2% and 0.7%, respectively.

Elsewhere, Argentina's MerVal index .MERV rose more than 1.3% as data showed inflation stood at 3.5% in September on a monthly basis, in line with a Reuters poll forecast and down from 4.2% in August.

Key Latin American stock indexes and currencies:


Latin American market prices from Reuters



Equities

Latest

Daily % change

MSCI Emerging Markets .MSCIEF

1156.36

0.7

MSCI LatAm .MILA00000PUS

2194.8

0.53

Brazil Bovespa .BVSP

130275.01

0.24

Mexico IPC .MXX

52367.99

0.96

Chile IPSA .SPIPSA

6578.77

0.57

Argentina Merval .MERV

1795701.47

1.341

Colombia COLCAP .COLCAP

1310.98

0.74




Currencies

Latest

Daily % change

Brazil real BRL=

5.5844

0.17

Mexico peso MXN=

19.4887

0.01

Chile peso CLP=

929.1

0.36

Colombia peso COP=

4199.85

0.84

Peru sol PEN=

3.769

-1.32

Argentina peso (interbank) ARS=RASL

974.5

0.05

Argentina peso (parallel) ARSB=

1160

1.29





Reporting by Johann M Cherian in Bengaluru; Editing by Philippa Fletcher and Matthew Lewis

</body></html>

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.